Genomic landscape of pathogenic mutation of APC, KRAS, TP53, PIK3CA, and MLH1 in Indonesian colorectal cancer

被引:9
|
作者
Marbun, Vania Myralda Giamour [1 ]
Erlina, Linda [2 ]
Lalisang, Toar Jean Maurice [1 ]
机构
[1] Univ Indonesia, Fac Med, Dept Gen Surg, Digest Div, Jakarta, Indonesia
[2] Univ Indonesia, Fac Med, Dept Med Chem, Jakarta, Indonesia
来源
PLOS ONE | 2022年 / 17卷 / 06期
关键词
E-CADHERIN; CATENIN; RAS; P53;
D O I
10.1371/journal.pone.0267090
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Colorectal cancer (CRC) needs several mutations to occur in various genes, and can vary widely in different individuals; hence it is essential to be discovered in a specific population. Until recently, there has been no known study describing APC, TP53, PIK3CA, KRAS, and MLH1 of CRC in Indonesian population. This study describes the nature and location of mutation in CRC patients treated at three different hospitals in Jakarta. Methods This descriptive study was conducted on CRC patients who underwent neoadjuvant, surgical, and adjuvant therapy at RSCM, RSKJ, and MRCCC in 2017-2018. DNA analysis was performed using next-generation sequencing and aligned against GRCh38. The pathogenic variant was identified using ACMG classification and FATHMM score. Data related to behavior and survival were collected from medical records. Results Twenty-two subjects in which APC, TP53, and PIKCA were mutated. KRAS mutation occurred in 64%, while MLH1 in 45%. There were five mutation types: nonsense, missense, frameshift, splice-site, and silent mutation. There are four groups of co-occurring mutations: APC, TP53, PIK3CA (triple mutation/TM) alone; TM+KRAS; TM+MLH1; and TM+KRAS +MLH1, presenting different nature and survival. Conclusion Indonesia has a distinct profile of pathogenic mutation, mainly presenting with locally-advanced stage with various outcomes and survival rate.
引用
收藏
页数:14
相关论文
共 42 条
  • [1] Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer
    Zhao, Jiayi
    Han, Yiping
    Li, Jiamei
    Chai, Rong
    Bai, Chong
    ONCOLOGY LETTERS, 2019, 17 (03) : 3233 - 3240
  • [2] TP53, PIK3CA, FBXW7 and KRAS Mutations in Esophageal Cancer Identified by Targeted Sequencing
    Zheng, Huili
    Wang, Yan
    Tang, Chuanning
    Jones, Lindsey
    Ye, Hua
    Zhang, Guangchun
    Cao, Weihai
    Li, Jingwen
    Liu, Lifeng
    Liu, Zhencong
    Zhang, Chao
    Lou, Feng
    Liu, Zhiyuan
    Li, Yangyang
    Shi, Zhenfen
    Zhang, Jingbo
    Zhang, Dandan
    Sun, Hong
    Dong, Haichao
    Dong, Zhishou
    Guo, Baishuai
    Yan, He
    Lu, Qingyu
    Huang, Xue
    Chen, Si-Yi
    CANCER GENOMICS & PROTEOMICS, 2016, 13 (03) : 231 - 238
  • [3] Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study
    Jauhri, Mayank
    Bhatnagar, Akanksha
    Gupta, Satish
    Bp, Manasa
    Minhas, Sachin
    Shokeen, Yogender
    Aggarwal, Shyam
    TUMOR BIOLOGY, 2017, 39 (02)
  • [4] Acquired somatic TP53 or PIK3CA mutations are potential predictors of when polyps evolve into colorectal cancer
    Chang, Pi-Yueh
    Chen, Jinn-Shiun
    Chang, Shih-Cheng
    Wang, Mei-Chia
    Chang, Nai-Chung
    Wen, Ying-Hao
    Tsai, Wen-Sy
    Liu, Wei-Hsiu
    Liu, Hsiu-Ling
    Lu, Jang-Jih
    ONCOTARGET, 2017, 8 (42) : 72352 - 72362
  • [5] PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal cancer patients
    Li, A-Jian
    Li, Hua-Guang
    Tang, Er-Jiang
    Wu, Wei
    Chen, Ying
    Jiang, Hui-Hong
    Lin, Mou-Bin
    Yin, Lu
    WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (05) : 631 - 640
  • [6] Clinical, Pathological and Molecular Insights on KRAS, NRAS, BRAF, PIK3CA and TP53 Mutations in Metastatic Colorectal Cancer Patients from Northeastern Romania
    Afrasanie, Vlad-Adrian
    Marinca, Mihai-Vasile
    Gafton, Bogdan
    Alexa-Stratulat, Teodora
    Rusu, Alexandra
    Froicu, Eliza-Maria
    Sur, Daniel
    Lungulescu, Cristian Virgil
    Popovici, Larisa
    Lefter, Andrei-Vlad
    Afrasanie, Irina
    Ivanov, Anca-Viorica
    Miron, Lucian
    Rusu, Cristina
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (16)
  • [7] MLH1 promoter hypermethylation in uterine carcinosarcoma rarely coexists with TP53 mutation
    Kunc, Michal
    Gabrych, Anna
    Rekawiecki, Bartlomiej
    Gorczynski, Adam
    Franke, Sabine
    Haybaeck, Johannes
    Biernat, Wojciech
    Czapiewski, Piotr
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2019, 23 (04): : 202 - 207
  • [8] Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes
    Kotoula, Vassiliki
    Karavasilis, Vasilios
    Zagouri, Flora
    Kouvatseas, George
    Giannoulatou, Eleni
    Gogas, Helen
    Lakis, Sotiris
    Pentheroudakis, George
    Bobos, Mattheos
    Papadopoulou, Kyriaki
    Tsolaki, Eleftheria
    Pectasides, Dimitrios
    Lazaridis, Georgios
    Koutras, Angelos
    Aravantinos, Gerasimos
    Christodoulou, Christos
    Papakostas, Pavlos
    Markopoulos, Christos
    Zografos, George
    Papandreou, Christos
    Fountzilas, George
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 158 (02) : 307 - 321
  • [9] Association of DCC, MLH1, GSTT1, GSTM1, and TP53 gene polymorphisms with colorectal cancer in Kazakhstan
    Djansugurova, Leyla
    Zhunussova, Gulnur
    Khussainova, Elmira
    Iksan, Olzhas
    Afonin, Georgiy
    Kaidarova, Dilyara
    Parker, M. Iqbal
    TUMOR BIOLOGY, 2015, 36 (01) : 279 - 289
  • [10] Discordance of PIK3CA and TP53 mutations between breast cancer brain metastases and matched primary tumors
    Thulin, Anna
    Andersson, Carola
    Ronnerman, Elisabeth Werner
    De Lara, Shahin
    Chamalidou, Chaido
    Schoenfeld, Arnd
    Kovacs, Aniko
    Fagman, Henrik
    Enlund, Fredrik
    Linderholm, Barbro K.
    SCIENTIFIC REPORTS, 2021, 11 (01)